Mechanism of HMGB1–RAGE in Kawasaki disease with coronary artery injury

Biying Qian1,2,3, Hua Huang1,2, Mingye Cheng1,2, Tingting Qin1,2, Tao Chen1,2 and Jianmei Zhao1*

Abstract

Background: Kawasaki disease (KD) is a common, yet unknown etiology disease in Asian countries, which causes acquired heart disease in childhood. It is characterized by an inflammatory acute febrile vasculitis of medium-sized arteries, particularly the coronary arteries. High-mobility group box-1 protein (HMGB1) is a non-histone chromosomal-binding protein present in the nucleus of eukaryotic cells, which contains 215 amino acid residues. Although the cellular signal transduction mechanisms of HMGB1 are currently unclear, the important role of the receptor for advanced glycation end-products (RAGE), the main receptor for HMGB1 has been reported in detail. The purpose of our study was to verify the mechanism and clinical significance of HMGB1-RAGE in coronary artery injury of Kawasaki disease.

Methods: 52 blood samples of patients in KD were collected, and the coronary artery Z score was calculated according to the echocardiographic results. The Z score ≥ 2.0 was classified as coronary artery lesions (CAL); otherwise, it was no-coronary artery lesions (NCAL). In addition, the fever group and control group were set. Among them, the fever group were children with fever due to respiratory tract infection at the same period as KD (heat peak ≥ 38.5 ℃). The normal group were children at a routine physical examination in the outpatient clinic of Nantong University and the physical examination center of the child care insurance, and there were no infectious diseases and heart diseases. The serum levels of HMGB1, RAGE, and NF-κB in each group were detected by ELISA. The animal model of KD was established using the New Zealand young rabbits. We used RT-qPCR/H&E staining/immunohistochemistry/ELISA and western blot to detect the level of HMGB1/RAGE and NF-κB.

Results: In this study, we found that the HMGB1/RAGE/NF-κB axis was elevated in the serum of children with KD. In addition, an animal model of KD was subsequently prepared to examine the pathological changes of the coronary arteries. We found that the serum levels of HMGB1/RAGE/NF-κB in rabbits with KD were significantly higher than those of the control group. Moreover, the lumen diameter of the coronary artery was slightly enlarged, and the wall of the tube became thinner and deformed. In addition, the HMGB1/RAGE/NF-κB levels in the coronary artery were higher in the rabbits with KD in the acute phase.

Conclusions: On the whole, the findings of this study demonstrate that the expression of HMGB1/RAGE/NF-κB is altered at different stages of KD, suggesting that the HMGB1/RAGE/NF-κB signaling pathway plays an important role in vascular injury in KD. The results of this study may have important implications for the early warning of coronary artery lesions in KD.

Keywords: Kawasaki disease, Coronary artery lesion, HMGB1, RAGE

Background

Kawasaki disease (KD) is an autoimmune systemic vasculitis disease, which is common among children. It is self-limiting and often occurs in children under 5 years of age [1]. It can involve small and medium blood vessels,
particularly the coronary arteries, and can lead to coronary dilatation, stenosis, and aneurysms, as well as myocardial infarction [2]. The incidence of coronary artery lesions (CALS) is 25–30% in children without regular treatment, while it will be reduced to 5% with the correct treatment during the early period [3]. In developed countries, CALs caused by KD have replaced rheumatic fever as the most common acquired heart disease among children, and may become one of the risk factors for ischemic heart disease in adulthood. At autopsy, the coronary artery has been found to be the most damaging site. Other sites, include the aorta, abdominal aorta, carotid artery, subclavian artery, and pulmonary artery [4]. The pathological changes are similar to those of infant nodular polyarteritis, with arterial full-thickness inflammation, intimal thickening, granulocyte and monocyte infiltration, internal elastic layer and medial wall necrosis, and aneurysm formation. However, with the increasing number of new medications being developed, and the use of intravenous immunoglobulin (IVIG) therapy, the mortality rate of patients with KD has markedly decreased, and thus the amount of corpses available for autopsy has also reduced. Thus, it is rare for scientists to be able to obtain a coronary artery for the use in further research [5]. Therefore, in this study, a rabbit model of KD was established, and the pathogenesis of KD was further explored at the histological and molecular levels.

High-mobility group box-1 protein (HMGB1) belongs to the HMG family, and is a highly conserved non-histone DNA-binding protein which is widely present in the eukaryotic cell [6, 7]. When the cells in the body are damaged or become necrotic, HMGB1 is passively released into the nucleus. Biologically activated HMGB1 promotes immune cells, including various cytokines (such as TNF-α and IL-1) and chemokines, maturation, and migration. Following the synthesis and release of HMGB1, pro-inflammatory factors, such as TNF-α and IL-1 further promote mononuclear/macrophages, endothelial cells, neuronal cells, NK cells, and other cells to actively secrete HMGB1; thus, forming a positive feedback loop. This leads to the continuous promotion of the inflammatory response [6, 8, 9].

The receptor for advanced glycation end products (RAGE) is a high-affinity receptor of HMGB1 currently known, while not the only receptor for HMGB1 [10]. RAGE is expressed in various types of cells, such as smooth muscle cells, endothelial cells, nerve cells, monocytes/macrophages, and others [11]. Under normal conditions, RAGE is expressed at low levels on the cell surface. However, when its ligand molecule increases, the expression of RAGE is up-regulated. The binding of HMGB1 to RAGE promotes the activation of mitogen, and the phosphorylation of protein kinases (such as p38 kinase, SAPK/JNK, and ERK1/2), and subsequently activates various signaling pathways, such as NF-κB and MAPKp38, inducing the production of inflammatory cytokines and chemokines [12]. Moreover, it is involved in the process of immune cell maturation, axon growth, and tumor proliferation [13]. To date, approximately 6 isoforms including the full-length transmembrane receptor have been found and 5 of these 6 isoforms lack the transmembrane domain, and are thus believed to be secreted from cells. Generally, these isoforms are referred to as soluble RAGE (sRAGE) or endogenous secretory RAGE (esRAGE) [14, 15].

The serum levels of HMGB1 have been shown to be significantly increased in the acute phase of KD [16]. A previous study demonstrated that in the acute phase of KD, the serum levels of HMGB1 were higher than those observed upon recovery [17]. In addition, in the acute phase of KD, HMGB1 is involved in the inflammatory reaction and coronary artery lesions become more heavily calcified; however, the exact mechanisms responsible for this injury remain unclear.

In this pilot study, we examined the hypothesis that the expression of HMGB1/RAGE/NF-κB in children with KD and in a rabbit model of KD could be altered. This change could be observed in CALs caused by KD. Moreover, the pathological mechanisms of coronary artery injury in KD were further investigated. For this purpose, serum from children with KD was collected at the acute phase and recovery phase at first. Subsequently, a rabbit model of KD was constructed. We further aimed to prove our hypothesis through research experiments, such as hematoxylin–eosin staining, immunohistochemistry, western blot analysis, ELISA, etc.

Materials and methods

Z score
The Z score uses body surface area as the normalized dimension (mean standard deviation) and standardized regression analysis based on continuous measurements, allowing comparison across time and population [18]. ① The inside diameter of those with no dilatation of the coronary arteries was always less than 2.0; ② only during the expansion, the Z score was 2.0 to 2.5, or the first Z score was less than 2.0, and the Z score decreased by more than 1 at follow-up review; ③ small tumor 2.5 < Z score < 5; ④ medium tumor 5 ≤ Z score < 10, and the absolute value of the inner diameter is < 8 mm; ⑤ the value of large or large tumors is ≥ 10, or the absolute value of the inner diameter is > 8 mm [19]. At present, coronary Z score obtained by echocardiography has become the main follow-up method for children with KD. There are many formulas currently for calculating the Z score, such as in...
the United States, Japan, Singapore, and Canada. The following two Z score calculation sites are provided from [https://raise.umin.jp/zsp/calculator/](https://raise.umin.jp/zsp/calculator/) from the Scientific Committee of the Kawasaki Disease Society of Japan and [https://zscore.chboston.org/](https://zscore.chboston.org/) from the Heart Center of Boston Children’s Hospital in the United States.[20]

We used a database recommended by Japan. According to the Z score (≥ 2.0), we determined the presence of a coronary artery lesion, and the children in acute phase of KD were divided into the CAL group and NCAL group.

**Patient specimen of KD**
All patients diagnosed with KD had fever for at least 5 days and met at least 4 of the 5 clinical criteria for KD (rash, conjunctival injection, cervical lymphadenopathy, oral mucosal changes, and changes in the extremities), or 3 of the 5 criteria along with coronary artery abnormalities documented by an echocardiogram [21]. Patients diagnosed with acute upper respiratory infection and herpangina were prospectively enrolled as febrile control subjects. In this study, the serum of 52 children with acute KD, 14 healthy controls, 14 febrile children, 44 convalescent KD children, and 44 children with subacute KD was collected from The Affiliated Hospital of Nantong University (Nantong, China) between April, 2018 and December, 2018 (Table 1). The investigation conformed with the principles outlined in the Declaration of Helsinki. The collected specimens were centrifuged to separate the serum, and then stored in −80˚C until use. The study protocol was approved by the Institution Review Board of The Affiliated Hospital of Nantong University. Informed consent was obtained from the parents.

**Preparation of animal models, animal sacrificing and materials**
The Laboratory Animal Ethics Committee of Nantong University approved the design of this study. The care and handling of rabbits followed the guidelines for the Administration of Experimental Animals of Jiangsu province. Eighteen male and female weanling New Zealand rabbits at 4–5 weeks of age and each weighing 500–1,000 g were purchased from Jiangsu Zhenlin Biotechnology Co., Ltd. [License No.: SCXK (Su) 2016–0008]. The rabbits were randomly and equally divided into 3 groups as follows: The normal group (N), the severe group (S), and the recovery group (R). The rabbits in group S and R received an intravenous (i.v.) injection twice into the marginal ear vein of 3.0 ml/kg BSA (10%, Shanghai Shenggong Bioengineering Co., Ltd., batch number AD0023) respectively, at 14-day intervals [22]. The animals in group N received 3.0 ml/kg saline in the same time with group S and R. On the 10th day after the establishment of the model (acute phase), 5 ml of arterial/venous blood of group N and S was acquired from the heart, and the rabbits in group S were anesthetized with pentobarbital, and the heart was rapidly removed. The coronary artery was picked out under a microscope and removed. The left anterior descending artery was fixed with 4% paraformaldehyde, and other coronary artery branches were stored at −80˚C. On the 28th day of the model (recovery period), blood was collected from the hearts of the remaining rabbits in groups N and R, and coronary artery specimens were acquired in the same manner.

**Hematoxylin–eosin (H&E) staining and immunohistochemical staining**
The left anterior descending artery was fixed with 4% paraformaldehyde for 24 h, then dehydrated by 20% sucrose solution for 24 h, and 30% sucrose was allowed to sink for 24 h. The tissue was embedded with an OCT frozen section embedding agent (Sakura, stock no. 4583) and sliced on a cryostat (Leica CM1900 UV) to a thickness of 6 μm. This was followed by H&E staining, alcohol dehydration,

| Groups | Normal | Febrile | Convalescent KD | Subacute KD | Acute KD |
|--------|--------|---------|-----------------|-------------|---------|
|        | CAL    | NCAL    | CAL             | NCAL        |         |
| Number | 14     | 14      | 44              | 44          | 10      | 42      |
| Male   | 6 (42.9%) | 7 (50%) | 28 (63.6%)      | 26 (59.1%)  | 6 (60%) | 25 (59.5%) |
| Female | 8 (57.1%) | 7 (50%) | 16 (36.4%)      | 18 (40.9%)  | 4 (30%) | 17 (40.5%) |
| Age (months) | 22.09 ± 19.08 | 40.45 ± 20.63 | 31.27 ± 24.64 | 28.37 ± 21.63 | 29.0 ± 22.36 | 25.42 ± 25.23 |
| WBC (× 10^9/L) | 4.34 ± 3.01 | 10.52 ± 6.25 | 7.24 ± 4.25 | 10.73 ± 4.97 | 12.13 ± 5.37 | 13.26 ± 6.02 |
| PLT (× 10^9/L) | 282.05 ± 103.61 | 304.42 ± 95.73 | 574.19 ± 152.81 | 458.52 ± 187.63 | 389.00 ± 74.94 | 370.68 ± 146.65 |
| Z score | – | – | – | – | 2.27 ± 0.19 | 0.14 ± 0.54 |

The values were expressed as the means ± SD. The Z scores were calculated by the website of [https://raise.umin.jp/zsp/calculator/](https://raise.umin.jp/zsp/calculator/)

KD Kawasaki disease, WBC white blood cell, PLT platelet
xylene transparentizion, and neutral gum sealing. For immunohistochemical staining, the sections were washed with 0.01 mol/l phosphate buffer for 5 min, 3 times, and the citrate buffer was autoclaved for antigen retrieval. The immunohistochemical two-step test kit (Nakasu Jinqiao, item no. PV-9000) was used in this experiment. First, the endogenous peroxidase blocker was applied for 20 min, then blocked with goat serum for 30 min, and the antibody was added in a dropwise manner overnight (Abcam, ab49849, 1:1,000). After the second day of rewarming, the reaction enhancer fluid was added for 20 min to enhance antigen–antibody combination. The enzyme-labeled goat anti-mouse/rabbit IgG polymer was then added for 20 min, plus DAB color developing agent for 10 s, and the nuclei were counterstained with hematoxylin for 10 s. Finally, alcohol gradient was used for dehydration, xylene for transparentizion, and neutral balsam for sealing. This was followed by observation under an optical microscope and filming. Coronary artery tissue was analyzed using ImageJ software, and the positive expression absorbance values of brown-yellow particles on the coronary arteries were counted.

Total RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
A total of 2 ml of whole blood was immediately injected into heparin anticoagulation tubes, and lymphocyte separation solution was added (Institute of Hematology, Chinese Academy of Medical Sciences); the peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation. Total RNA was isolated using Trizol reagent (Shanghai Shenggong Bioengineering Co., Ltd.). The concentration and purity of the extracted RNA were measured spectrophotometrically at A260 and A280. Total RNA 2 μg was reverse transcribed into cDNA was using the RevertAid First Strand cDNA Synthesis Kit. According to the sequence of GenBank, primers were designed using Primer Premier 5.0 and synthesized by Shanghai Bioengineering Technology Service Co., Ltd. PCR amplification was performed using SYBR-Green master mix and real-time PCR instrumentation using RT-PCR. All real-time PCRs were performed at least in triplicate. Primer sequence of HMGB1, RAGE and NF-κB are as follows: HMGB1 forward, AGC CGA TCA TGT CA and reverse, AGT  TGA CGG ACTG and reverse, CTG  CTG TCA CCT TCA CCG GAATG; and β-actin forward, GCA  AGT GCT TCT AGG TTCC.

Enzyme-linked immunosorbent assay (ELISA)
The serum level of HMGB1/RAGE and NF-κB in children and the rabbits in the model of KD were measured using ELISA kits (Shanghai Enzyme-linked Biotechnology Co., Ltd.) according to the manufacturer’s instructions. RAGE measured in serum is referred to sRAGE.

Western blot analysis
Protein extracts from the coronary artery were separated by SDS-PAGE (11–15% acrylamide). After being transferred to PVDF membranes and blocking for 2 h, primary antibody was added overnight, followed by washing in PBS, application of a secondary HRP-conjugated antibody and development using an ECL system (Absin Bioscience). Rabbit anti-HMGBl (1:1,000; Abcam, ab18256), goat anti-RAGE (1:1,000; RD systems, AF1145), rabbit anti-NF-κB (1:1,000; Cell Signaling Technology, 8242) mouse anti-β-actin (1:1,000; Proteintech, 60,008-1-lg) were used as primary antibodies. All western blots in this study were subjected to different exposures: From 10 s to 10 min, and the optimal exposures were selected for data presentation.

Statistical analysis
Histological images were acquired with an Olympus BX51 microscope with objective lenses of Plan Apo at ×10, ×20, and ×40 magnifications and with a color CCD camera (DFC320, Leica) for digital micrographs. For the quantification of positive values, digital micrographs of brown granules of specimens stained by DAB were processed by binarization of the images with ImageJ software. Quantitative data are presented in bar graphs. All investigated variables were normally distributed. Statistical analyses were conducted with SPSS software. Comparisons between 2 groups were carried out using t test, and those among multiple groups were carried out using Tukey’s honestly significant difference analysis. For all analyses, $P<0.05$ was considered to indicate a statistically significant difference.

Results
Expression of HMGB1/sRAGE/NF-κB in KD children
ELISA was used to detect the expression levels of HMGB1/sRAGE/NF-κB in children with KD. We found that the expression of the above-mentioned indicators markedly increased in the acute phase of KD. As the disease recovered, the index gradually decreased in the sub-acute phase and recovery phase. The results revealed that the levels of the above-mentioned indicators were significantly higher in the CAL group, and the difference was statistically significant compared with the NCAL group ($P<0.05$) (Fig. 1).
We then established a young rabbit model of KD to further examine the association between HMGB1-RAGE with KD and KD CAL.

**Histological changes in the coronary arteries of the rabbit model for KD**

**H&E staining**

The results revealed that the coronary artery structure of the normal group (group N) was clear, the intima was evident, the lumen size was moderate, and the thickness was uniform; however, in the coronary artery of the acute phase group (group S), the lumen was slightly enlarged, the wall of the tube became thinner, and the middle layer was more evident. In the recovery group (group R), the coronary artery became larger and the wall became thinner and deformed. In short, the coronary artery of the S group has begun to change, but not as obvious as the R group (Fig. 2a).

**Immunohistochemical staining**

The main expression of brown-yellow particles in the intima endothelial cells was observed. HMGB1 was mainly expressed in the nucleus of endothelial cells, and was also expressed at low levels in smooth muscle cells. RAGE and NF-κB were expressed in both the nucleus and cytoplasm (Fig. 2b). Positive expression levels of HMGB1 in group N, group S, and group R were 5.21 ± 1.35, 14.55 ± 2.01 and 6.24 ± 1.17, respectively; those of RAGE were 6.75 ± 1.27, 13.15 ± 1.64 and 8.37 ± 0.77, and those of NF-κB were 6.19 ± 0.89, 11.81 ± 1.44 and 6.59 ± 0.84.
Fig. 2 The coronary artery structure in group N was clear, the intima was evident, the lumen size was moderate, and the thickness was uniform; however, in group S, the lumen was slightly enlarged, the wall of the tube became thinner, and the middle layer was more evident. In the group R, the coronary artery became larger and the wall became thinner and deformed. The arrow points to the coronary artery. The picture showed the results in three kinds of magnification multiple: ×100, ×200, ×400 (a). As indicated by the arrow, the brown-yellow particles can be seen in the endothelial cells and in the smooth muscle cells. And HMGB1/RAGE/NF-κB levels were highly expressed in the group S analyzed by ImageJ (×400) (b).
respectively. The levels in group S were higher than those in group N and group R, and those in group R were slightly higher than those in group N. The difference was statistically significant \( (P < 0.05) \).

**Changes in mRNA expression in the PBMCs rabbit model of KD**

For the rabbit model of KD, the levels of HMGB1/RAGE/NF-κB mRNA in PBMCs of groups N/S/R were as follows: HMGB1: 1.0 ± 0.01, 10.95 ± 0.65 and 5.25 ± 0.47; RAGE: 1.00 ± 0.06, 5.50 ± 0.39 and 1.47 ± 0.18; NF-κB: 1.00 ± 0.13, 6.55 ± 0.95 and 2.07 ± 0.23. The values in group S were significantly higher than those in group N and group R with statistical significance \( (P < 0.05) \). For HMGB1, the values in group R were slightly higher than those in group N. The difference was statistically significant \( (P < 0.05) \). For RAGE and NF-κB, the values in group R were slightly higher than those in the normal group, although the difference was not statistically significant \( (P > 0.05) \) (Fig. 3a).

**Protein expression relative levels in the rabbit model of KD Western blot analysis**

Western blot analysis revealed that the HMGB1/RAGE/NF-κB protein level was up-regulated in group S in the young rabbit model of KD, compared with group R and group N, with statistical significance \( (P < 0.05) \). The levels in the recovery group were higher than those in the normal group, and the difference was statistically significant \( (P < 0.05) \) (Fig. 3b).

**ELISA**

Subsequent ELISA revealed that the protein levels of HMGB1/sRAGE/NF-κB in group S were significantly higher than those in group N and R \( (P < 0.05) \). In group R, the levels of HMGB1/sRAGE/NF-κB were still higher than those of group N, although there was no significant difference compared with group N \( (P > 0.05) \) (Fig. 3c).

**Discussion**

Kawasaki disease is a juvenile idiopathic immune disease that is the leading cause of childhood acquired heart disease [23]. Once a coronary artery lesion is formed, which is known as a coronary aneurysm, it may cause lifelong harm to the child and may even cause sudden death. Many researchers have proven that the early detection of correct treatment can prevent coronary aneurysms. High-mobility group box-1 (HMGB1), also known as amphoterin protein, is a type of non-group DNA-binding protein that is widely distributed in higher eukaryotes, and is secreted outside the cell following tissue damage or stimulation by pathogens, which induces different inflammatory processes [7]. HMGB1 needs to bind to receptors on the surface of target cell membranes, and can then be synthesized and released by signal transduction systems, such as mitogen-activated protein kinases (MAPK) and nuclear factor (NF)-κB. Currently, the receptor for advanced glycation end products (RAGE), Toll-like receptor 2 (TLR2), and Toll-like receptor 4 (TLR4) have been found [24]. RAGE belongs to the immunoglobulin superfamily transmembrane receptor, and is expressed in endothelial cells, smooth muscle cells, neuronal cells, monocyte macrophages, and various stem cells [25]. After binding to HMGB1, RAGE mediates multiple intracellular signaling pathways, including NF-κB, JAK/STAT, and MAPK families, and exerts a wide range of physiological and pathological effects [26]. HMGB1 levels have been shown to be higher in 27 children by KD than in healthy controls, as measured by Hoshina [27–29].

In order to be consistent with these studies, we collected serum samples from children in different phases of KD. Due to the current timely treatment of Kawasaki disease, the incidence of coronary artery injury is greatly reduced, so only 10 CAL cases were collected in this study. We found that the expression of HMGB1/sRAGE/NF-κB increased in the acute phase of KD. Notably, in the acute phase of KD, the CAL group exhibited higher levels than the NCAL group, as regards these three indicators [30]. Furthermore, we established a rabbit model of KD. By observing the pathological sections of the coronary artery at different stages, we found that the coronary artery of the rabbit model of KD exhibited luminal dilatation, and the wall had become thinner and deformed. The pathological changes in the coronary arteries in rabbits are similar to those in children with KD. We further found that HMGB1, RAGE, and NF-κB were located in the endothelial cells of the coronary arteries, in which HMGB1 was mainly expressed in the nucleus, and RAGE and NF-κB are in both the nucleus and cytoplasm. By detecting the expression of HMGB1, RAGE, and NF-κB in coronary endothelial cells, we found that the levels of the three indicators were increased in the S group, and in PBMCs that the mRNA expression of HMGB1, RAGE, and NF-κB were also increased. By detecting the expression of HMGB1, sRAGE, and NF-κB in serum, we found that the levels of the three indicators were increased in the S group. Although there are reports that sRAGE is reduced in the acute phase of KD [31], we tested the serum of patients with KD and in a young rabbit model of KD, and found that it was increased in the acute phase, which may be related to the number of cases or time or regional disparity. In addition, some studies have reported that sRAGE is elevated in the acute phase of some diseases; for example, in patients with infection-related ARDS, sRAGE levels have been shown to be
much higher than those in the control subjects [32]. In summary, we hypothesized that HMGB1-RAGE may be associated with the development of KD; particularly, in the acute phase when HMGB1 accumulates in coronary endothelial cells, causing coronary vasculitis and promoting coronary artery dilatation. We aim to carry out further research to confirm these results. In summary, HMGB1 can be used as an indicator of inflammation in KD, and has a high clinical value in suggesting coronary artery injury. Therefore, the clinical treatment of KD with active anti-inflammatory, anticoagulant, high-dose gamma globulin infusion, etc., can also block the secretion of HMGB1 at an early stage to prevent coronary artery injury and reduce the occurrence of coronary
aneurysms. Limitations of this study: The effect of HMGB1 inhibitors on KD young rabbits has not been verified from animal experiments.

**Conclusion**

The findings of this study indicate that the expression of HMGB1, RAGE, and NF-κB were significantly increased in the acute phase of children with KD, which was of great value for the early diagnosis of KD, and the expression of HMGB1, RAGE, and NF-κB in CAL group were significantly higher than that in NCAL group, which indicate that it is involved in the occurrence and development of KD coronary injury. The expression of HMGB1, RAGE, and NF-κB were significantly elevated in the coronary artery of young rabbits with KD, and its expression was localized in endothelial cells, which may play an important role in the occurrence of KD coronary artery lesion, while its exact mechanisms of action warrant further investigation.

**Abbreviations**

KD: Kawasaki disease; CAL: Coronary artery lesions; NCAL: No coronary artery lesions; HMGB1: High-mobility group box-1 protein; RAGE: Receptor for advanced glycation end-products; NF-κB: Nuclear factor kappa-B; IVIG: Intravenous immunoglobulin; PBMC: Peripheral blood mononuclear cell; MAPK: Mitogen-activated protein kinase; ARDS: Acute respiratory distress syndrome; SAPK: Stress-activated protein kinase; BSA: Bovine serum albumin; ERK: Extracellular regulated protein kinases; OCT: Hematoxylin–eosin; ELISA: Enzyme-linked immunosorbent assay; PVDF: Polyvinylidene fluoride; TLR: Toll-like receptor.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

JZ conceived and designed the experiment, performed the experiments, BQ analyzed the data and wrote the manuscript. BQ/AHH/MC reviewed the research program and coordinated work. BQ/TQ/TC performed the experiments and analyzed the data. All authors read and approved the final manuscript.

**Funding**

Postgraduate Research & Practice Innovation Program of Jiangsu Province (SSJKX17-0644); Nantong City Social and People’s Livelihood Science and Technology Key Projects (MS22019001); the Scientific Research Program of Jiangsu Province Health Department (H201423); Jiangsu Province Maternal and Child Health Research Project (F2017751).

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Ethics approval and consent to participate**

The study protocol was approved by the Institution Review Board of The Affiliated Hospital of Nantong University. Informed consent was obtained from the parents. And the Laboratory Animal Ethics Committee of Nantong University approved the design of this study too.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Author details**

1 Department of Paediatrics, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, People's Republic of China. 2 Medical College of Nantong university, Nantong 226001, Jiangsu, People's Republic of China. 3 Department of Emergency Medicine, Shanghai Children’s Hospital, Shanghai Jiaotong University, Shanghai 200062, People's Republic of China.

Received: 24 June 2019  Accepted: 18 February 2020

Published online: 17 March 2020

**References**

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271–6.

2. Gurofsky RC, Sabharwal T, Manihot C, et al. Arterial complications associated with cardiac catheterization in pediatric patients with a previous history of Kawasaki disease. Catheter Cardiovasc interv. 2009;73:809–13.

3. Buonsenso D, Cristaldi S, Reale A, de Jacobis I, Granata L, Marches A. Very early development and recognition of coronary involvement in a febrile infant with typical signs of Kawasaki disease. Mediterr J Hematol Infect Dis. 2018;10:e2018037.

4. ElGuindy MS, ElGuindy AM. Aneurysms of coronary arteries: an overview. Global Cardiol Sci Pract. 2017;2017:e201726.

5. Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease. Paediatr Int Child Health. 2018;38:209–12.

6. Sohun M, Shern H. The implication and potential applications of high-mobility group box 1 protein in breast cancer. Ann Trans Med. 2016;4:217.

7. Andersson U, Yang H, Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin Immunol. 2018;38:40–8.

8. Gougeon ML, Poirier-Beaudouin B, Durant J, et al. HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-associated neurocognitive Is orders (HAND). Heliyon. 2017;3:e00245.

9. Liu X, Xu Q, Mei L, et al. Paenol attenuates acute lung injury by inhibiting HMGB1 in lipopolysaccharide-induced shock rats. Int Immunopharmacol. 2018;61:169–77.

10. Ullah MA, Loh Z, Gan WJ, et al. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation. J Allergy Clin Immunol. 2014;134:440–50.

11. Wu H, Li R, Pei LG, et al. Emerging role of high mobility group box-1 in thrombosis-related diseases. Cell Physiol Biochem. 2018;47:1319–37.

12. Jiang Y, Steinle JJ. HMGB1 inhibits insulin signalling through TLR4 and RAGE in human retinal endothelial cells. Growth Factors (Chur, Switzerland). 2018;36:164–71.

13. Palanissami G, Paul SF. RAGE and its ligands: molecular interplay between glycation, inflammation, and hallmarks of cancer-a review. Horm Cancer. 2018;9:295–325.

14. Ilzecka J. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2009;120:119–22.

15. Ding Q, Keller JN. Evaluation of rage isoforms, ligands, and signaling in the brain. Biochem Biophys Acta. 2005;1746:18–27.

16. de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev. 2012;11:909–17.

17. Yarui J. Jl. The expression and clinical significance of high mobility group protein B1 in KD. China Modern Doctor. 2009;47:Issue 15.

18. Jcs Joint working group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Crc J. 2014;78:2521–62.
19. Manlhiot C, Millar K, Golding F, McCrindle BW. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol. 2010;31:242–9.
20. Li XF, Zheng P, Xu L and Su Q. (The influence of autoclave sterilization on surface characteristics and cyclic fatigue resistance of 3 nickel-titanium rotary instruments). Shanghai kou qiang yi xue = Shanghai J Stomatol. 2015;24:690–5.
21. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American heart association. Circulation. 2017;135:e927–e999999.
22. Onouchi Z, Ikuta K, Nagamatsu K, Tamiya H, Sakakibara Y, Ando M. Coronary artery aneurysms develop in weanling rabbits with serum sickness but not in mature rabbits. An experimental model for Kawasaki disease in humans. Angiology. 1995;46:679–87.
23. Newburger JW, Takahashi M, Burns JC. Kawasaki Disease. J Am Coll Cardiol. 2017;67:1738–49.
24. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple toll-like receptors. Am J Physiol Cell Physiol. 2006;290:C917–924.
25. Liu C, Kong X, Wu X, et al. Alleviation of a disintegrin and metalloprotease 10 (ADAM10) on thromboangiitis obliterans involves the HMGB1/RAGE/NF-kappaB pathway. Biochem Biophys Res Commun. 2018;505:282–9.
26. Tesarova P, Cabinakova M, Mikulova V, Zima T, Kalouseva M. RAGE and its ligands in cancer—culprits, biomarkers, or therapeutic targets? Neoplasma. 2015;62:353–64.
27. Hoshina T, Kusuhara K, Ikeda K, Mizuno Y, Saito M, Hara T. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease. Scand J Rheumatol. 2008;37:445–9.
28. deSouza AW, Abdulahad WH, Sosicka P, et al. Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis? Clin Exp Immunol. 2014;178:270–8.
29. Wang C, de Souza AW, Wiestra J, et al. Emerging role of high mobility group box 1 in ANCA-associated vasculitis. Autoimmun Rev. 2015;14:1057–65.
30. Nakaoka H, Hirono K, Yamamoto S, et al. MicroRNA-145-5p and microRNA-320a encapsulated in endothelial microparticles contribute to the progression of vasculitis in acute Kawasaki Disease. Sci Rep. 2018;8:1016.
31. Qi Y, Gong F, Zhang Q, Xie C, Wang W, Fu S. Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease. Arthritis Res Ther. 2012;14:R251.
32. Wang H, Wang T, Yuan Z, et al. Role of receptor for advanced glycation end products in regulating lung fluid balance in lipopolysaccharide-induced acute lung injury and infection-related acute respiratory distress syndrome. Shock (Augusta, Ga.). 2018;50:472–82.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.